Literature DB >> 18370775

Effects of antihypertensives on glucose metabolism.

David Siegel1, Arthur L M Swislocki.   

Abstract

Treatment with different antihypertensive drug classes has varied effects on glucose metabolism. Thiazide diuretic use in hypertensives has been associated with the development of glucose intolerance and diabetes. Some findings suggest that the probability of worsening glucose metabolism and the development of new diabetes after thiazide initiation is associated with increasing body mass index. Nonselective or beta(1) selective beta-blockers may also lead to decreased insulin sensitivity in hypertensive patients. Newer beta-blockers that cause vasodilatation and beta-blockers that have intrinsic sympathomimetic activity may not have these deleterious effects on insulin sensitivity and glucose metabolism. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers may exert beneficial effects on glycemic control through a variety of mechanisms related to the inhibition of angiotensin II. These agents may be particularly useful in patients with microalbuminuria to slow the progression of renal disease. While there may be some small differences among different classes of calcium channel blockers, there is little net effect of these agents on glucose metabolism. The prevalence of obesity, hypertension, and type 2 diabetes mellitus is increasing in the US. In this setting, it is important to individualize antihypertensive therapy and to monitor its metabolic consequences so that potential adverse effects that would negate some of the benefits of blood-pressure lowering are minimized.

Entities:  

Year:  2007        PMID: 18370775     DOI: 10.1089/met.2007.0016

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  7 in total

1.  Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Authors:  Zeina A Al-Thanoon; Isam H Mahmood
Journal:  Oman Med J       Date:  2012-01

2.  Effect of clonidine on blood glucose levels in euglycemic and alloxan-induced diabetic rats and its interaction with glibenclamide.

Authors:  S Manjunath; Santosh N Kugali; Priyadarshani M Deodurg
Journal:  Indian J Pharmacol       Date:  2009-10       Impact factor: 1.200

3.  Effects of dipeptidyl-peptidase 4 inhibitor about vascular inflammation in a metabolic syndrome model.

Authors:  Nicolas F Renna; Emiliano A Diez; Roberto M Miatello
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

4.  Role of Renin-Angiotensin system and oxidative stress on vascular inflammation in insulin resistence model.

Authors:  N F Renna; C Lembo; E Diez; R M Miatello
Journal:  Int J Hypertens       Date:  2013-01-08       Impact factor: 2.420

5.  Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients.

Authors:  Sandesh Madhukar Bharati; Nishith Singh
Journal:  J Pharmacol Pharmacother       Date:  2016 Apr-Jun

6.  The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α.

Authors:  Aaron L Magno; Lakshini Y Herat; Márcio G Kiuchi; Markus P Schlaich; Natalie C Ward; Vance B Matthews
Journal:  J Clin Med       Date:  2020-08-26       Impact factor: 4.241

7.  Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes Remission Clinical Trial (DiRECT).

Authors:  Wilma S Leslie; Eman Ali; Leanne Harris; C Martina Messow; Naomi T Brosnahan; George Thom; E Louise McCombie; Alison C Barnes; Naveed Sattar; Roy Taylor; Michael E J Lean
Journal:  Diabetologia       Date:  2021-05-31       Impact factor: 10.122

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.